Polyrizon (PLRZ) Total Current Liabilities (2023 - 2025)
Polyrizon's (PLRZ) quarterly Total Current Liabilities came in at $443000.0 in Q4 2025, up 69.73% YoY from $261000.0 in Q4 2024, and up 21.7% on a QoQ basis from $364000.0 in Q2 2025.
Polyrizon (PLRZ) Total Current Liabilities (2023 - 2025) Analysis & Trends
Polyrizon (PLRZ) has 3 years of Total Current Liabilities data on file, last reported at $443000.0 in Q4 2025.
- Quarterly Total Current Liabilities rose 69.73% year-over-year to $443000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $443000.0 (up 69.73% YoY) and the FY2025 annual result came in at $443000.0, up 69.73% from the prior year.
- Total Current Liabilities climbed to $443000.0 in Q4 2025, from $364000.0 in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $502000.0 in Q4 2023 to a low of $261000.0 in Q4 2024.
- A 3-year average of $392500.0 and a median of $403500.0 in 2025 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2024 — Total Current Liabilities tumbled 48.01% — and 2025, when it jumped 69.73%.
- Tracing PLRZ's Total Current Liabilities over 3 years: stood at $502000.0 in 2023, then plunged by 48.01% to $261000.0 in 2024, then jumped by 69.73% to $443000.0 in 2025.
- The last three Total Current Liabilities figures came in at $443000.0 (Q4 2025), $364000.0 (Q2 2025), and $261000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Polyrizon | 7.27 Mn | -4.22 Mn | - | 443,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 443,000.00 |
| Jun 30, 2025 | 364,000.00 |
| Dec 31, 2024 | 261,000.00 |
| Dec 31, 2023 | 502,000.00 |